Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 106Neoplasms 14Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Hereditary Sensory and Autonomic Neuropathies 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Recurrent Uterine Corpus Carcinoma 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Hormone Receptor Positive Breast Cancer 1HER2-positive Breast Cancer 1Female Breast Carcinoma 1Exanthema 1

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Uterine Corpus Carcinoma × Fulvestrant × Clear all
NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

GOG Foundation

Phase 2 Unknown
67 enrolled 9 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡